NCT04792073View on ClinicalTrials.gov

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 8, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Merkel Cell Carcinoma
Interventions
DRUG

Avelumab

Avelumab 800 mg given intravenously over 60 minutes (+20 minutes / -10 minutes) every 2 weeks (+/- 3 days)

RADIATION

Comprehensive Ablative Radiation Therapy

Comprehensive ablative radiation therapy 24 Gy in 3 fractions every 2-3 days

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale

11725

Memorial Sloan Kettering Commack (All Protocol Activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale

Sponsors

Collaborators (1)

EMD Serono
All Listed Sponsors
collaborator

EMD Serono

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT04792073 - Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma | Biotech Hunter | Biotech Hunter